{"With": [0], "the": [1, 61, 69, 123, 143, 168, 264], "emergence": [2], "of": [3, 50, 109, 187, 191, 220, 266, 270], "Alzheimer's": [4], "disease": [5], "(AD)": [6], "disease-modifying": [7, 148], "therapies,": [8], "identifying": [9], "patients": [10], "who": [11], "could": [12, 29], "benefit": [13], "from": [14], "these": [15], "treatments": [16], "becomes": [17], "critical.": [18], "In": [19, 193], "this": [20], "study,": [21], "we": [22], "evaluated": [23], "whether": [24], "a": [25, 211, 216, 243], "precise": [26], "blood": [27, 272], "test": [28], "perform": [30], "as": [31, 33, 122], "well": [32], "established": [34], "cerebrospinal": [35], "fluid": [36], "(CSF)": [37], "tests": [38, 158, 184, 262, 273], "in": [39, 60, 159, 185, 263, 274], "detecting": [40], "amyloid-\u03b2": [41], "(A\u03b2)": [42], "plaques": [43], "and": [44, 68, 73, 94, 100, 104, 138, 175, 215, 225, 284], "tau": [45, 113, 228], "tangles.": [46], "Plasma": [47, 150, 177], "%p-tau217": [48, 151, 178, 207, 248], "(ratio": [49], "phosporylated-tau217": [51], "to": [52, 155, 182, 235, 240, 257, 280], "non-phosphorylated": [53], "tau)": [54], "was": [55, 152, 179, 232, 252], "analyzed": [56, 90], "by": [57], "mass": [58], "spectrometry": [59], "Swedish": [62], "BioFINDER-2": [63], "cohort": [64, 82], "(n": [65, 83], "=": [66, 84, 199, 204], "1,422)": [67], "US": [70], "Charles": [71], "F.": [72], "Joanne": [74], "Knight": [75, 201], "Alzheimer": [76], "Disease": [77], "Research": [78], "Center": [79], "(Knight": [80], "ADRC)": [81], "337).": [85], "Matched": [86], "CSF": [87, 157, 183, 236, 261], "samples": [88], "were": [89, 107, 128], "with": [91, 132, 164, 189], "clinically": [92, 153, 233, 253, 258], "used": [93, 259], "FDA-approved": [95, 156, 260], "automated": [96], "immunoassays": [97], "for": [98, 146, 171, 222, 227], "A\u03b242/40": [99], "p-tau181/A\u03b242.": [101], "The": [102], "primary": [103], "secondary": [105], "outcomes": [106], "detection": [108, 265], "brain": [110], "A\u03b2": [111, 161, 223], "or": [112, 255], "pathology,": [114], "respectively,": [115], "using": [116, 242], "positron": [117], "emission": [118], "tomography": [119], "(PET)": [120], "imaging": [121], "reference": [124], "standard.": [125], "Main": [126], "analyses": [127], "focused": [129], "on": [130], "individuals": [131], "cognitive": [133, 136], "impairment": [134, 137], "(mild": [135], "mild": [139], "dementia),": [140], "which": [141, 231], "is": [142], "target": [144], "population": [145], "available": [147], "treatments.": [149, 286], "equivalent": [154, 234, 254], "classifying": [160], "PET": [162, 224, 229], "status,": [163, 230], "an": [165, 209], "area": [166], "under": [167], "curve": [169], "(AUC)": [170], "both": [172], "between": [173], "0.95": [174], "0.97.": [176], "generally": [180], "superior": [181, 256], "classification": [186], "tau-PET": [188], "AUCs": [190], "0.95-0.98.": [192], "cognitively": [194], "impaired": [195], "subcohorts": [196], "(BioFINDER-2:": [197], "n": [198, 203], "720;": [200], "ADRC:": [202], "50),": [205], "plasma": [206, 247], "had": [208], "accuracy,": [210], "positive": [212], "predictive": [213, 218], "value": [214, 219], "negative": [217], "89-90%": [221], "87-88%": [226], "tests,": [237], "further": [238], "improving": [239], "95%": [241], "two-cutoffs": [244], "approach.": [245], "Blood": [246], "demonstrated": [249], "performance": [250], "that": [251], "AD": [267, 282], "pathology.": [268], "Use": [269], "high-performance": [271], "clinical": [275], "practice": [276], "can": [277], "improve": [278], "access": [279], "accurate": [281], "diagnosis": [283], "AD-specific": [285]}